Fennec Pharmaceuticals (FENC) Misses Q4 EPS by 20c
Tweet
Share
E-mailGet Alerts FENC Hot Sheet
Join SI Premium – FREE
Fennec Pharmaceuticals (NASDAQ: FENC) reported Q4 EPS of ($0.17), $0.20 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $13.77 million versus the consensus estimate of $14.56 million.
For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leerink Starts Parabilis Medicines (PBLS) at Outperform
- BofA Securities Starts Parabilis Medicines (PBLS) at Buy
- Barclays Upgrades Lincoln National (LNC) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
